The Navigator Company (NVG) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 May, 2026Executive summary
Q1 2026 was marked by heightened geopolitical tensions and severe weather in Portugal, causing operational disruptions and increased costs.
Tissue and packaging segments contributed 40% of EBITDA, reflecting successful diversification and resilience.
Price increases across all segments reversed a six-quarter downward trend in the PIX A4 index and key paper indices.
Strategic initiatives included new product launches, partnerships, and capacity expansions, especially in tissue and packaging.
Financial highlights
EBITDA for Q1 2026 was EUR 65 million, down 14% sequentially and 44% year-over-year, with a margin of 15-15.2%.
Net debt reduced by EUR 28 million; net debt to EBITDA ratio at 2.08x.
Liquidity stood at EUR 570 million.
CapEx reached EUR 42 million, with 53% allocated to sustainability and ESG projects.
Turnover was €427M, down 19% year-over-year and 11% sequentially.
Outlook and guidance
Pulp prices expected to remain above 2025 levels, with further increases in Europe until Q3 and in China until Q2, followed by moderate corrections.
No significant new supply expected until 2027-2028, supporting a favorable supply-demand balance.
Multi-stage price increases underway in printing, writing, and packaging papers across all key markets.
Tissue demand remains strong, with 5-7% price increases effective May and new capacity planned for the UK.
Packaging segment to benefit from 5-10% price increases and continued demand growth.
Latest events from The Navigator Company
- Diversification into tissue and packaging offset profit declines amid challenging market conditions.NVG
Q4 202513 Apr 2026 - Record H1 2024: 9% revenue growth, 28% EBITDA margin, robust tissue gains, top ESG ranking.NVG
H1 20242 Feb 2026 - Turnover, EBITDA, and net profit rose double digits, led by tissue and packaging growth.NVG
Q3 202417 Jan 2026 - Turnover up 7% to €2.09B, EBITDA at €547M, net profit up 4%, and €175M dividend proposed.NVG
Q4 202416 Dec 2025 - Q1 2025 saw resilient growth, strong tissue and packaging, and stable margins.NVG
Q1 202519 Nov 2025 - Tissue and Packaging offset profit declines, with cost controls and sustainability investments supporting resilience.NVG
Q3 202531 Oct 2025 - Tissue and Packaging growth offset profit declines, with resilience amid global volatility.NVG
Q2 202530 Oct 2025